The popularity of Sildenafil initially sparked a period of growth for major pharmaceutical companies, but recent changes present a murky scenario for shareholders. Off-patent alternatives are eating into earnings, and https://jaysonnslc500303.idblogz.com/41529751/viagra-and-pharma-a-risky-bet